Skip to main content
Home > SciBX > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Table 1: A peek at PI3K inhibitors

    Targets & Mechanisms: PI3K inhibition: solid immunotherapy Table 1. A peek at PI3K inhibitors. According to a study in Nature by Ali et al., inhibition of phosphoinositide 3-kinase-d (PI3Kd) or the PI3K catalytic …

    Published on 6/26/2014
  • Managing meningitis

    SHX Vaccines is taking a different approach to vaccinating against meningitis -- preventing meningococci from binding to host cells in the first place. The company's academic collaborators have proof of concept for the …

    Published on 6/26/2014
  • PI3K inhibition: solid immunotherapy

    A new finding that links PI3Kdelta to T cell responses in a range of solid tumor types could expand use of PI3Kdelta inhibitors beyond the blood cancer setting and launch a new class of immunotherapies.

    Published on 6/26/2014
  • Collateral tumor damage

    Australian researchers have used T cells against antigens from a glioma cytomegalovirus rather than against tumor targets to attack brain cancer. The next step is to identify the best CMV epitopes for activating T cells…

    Published on 6/19/2014
  • CXCR2 antibodies for antitumor immunity

    An NCI team has identified a CXCR2-regulated pathway of tumor immune evasion that could account for some patients' resistance to checkpoint inhibitor-based therapies. The researchers are now planning to test anti-CXCR2 …

    Published on 6/19/2014
  • Figure 1: SMYD3 in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Figure 1. SMYD3 in cancer. Mazur et al. have identified the role of SET and MYND domain containing 3 (SMYD3) in K-Ras (KRAS)-driven lung and pancreatic cancers. In …

    Published on 6/12/2014
  • Table 1: Selected MAPK pathway compounds in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Table 1. Selected MAPK pathway compounds in cancer. Source: BCIQ: BioCentury Online Intelligence Company Compound Indication Target Status Amgen Inc. (NASDAQ:AMGN…

    Published on 6/12/2014
  • Box 1: Revisiting the pancreas

    Targets & Mechanisms: Stromal uncertainties in pancreatic cancer Box 1. Revisiting the pancreas. The insights into the nature of these aggressive, poorly differentiated pancreatic tumors suggest a niche for two …

    Published on 6/12/2014
  • Putting SMYD3 on the MAP

    Stanford and GlaxoSmithKline report that SMYD3 acts in the cytoplasm to regulate the MAPK pathway and not in the nucleus as previously thought. The discovery implies that inhibiting the enzyme can counter activating …

    Published on 6/12/2014
  • Stromal uncertainties in pancreatic cancer

    Despite the clear rationale for using hedgehog inhibitors in pancreatic cancer-they deplete the stroma to improve chemotherapy delivery-clinical results have been disappointing. New data suggest the large amounts of …

    Published on 6/12/2014
  • De-stressing glaucoma

    Glucocorticoids are standard care for a host of allergic and inflammatory eye conditions, but they can elevate intraocular pressure and result in secondary open-angle glaucoma. A chemical chaperone called sodium …

    Published on 6/5/2014
  • S100A9-clot not, bleed not

    U.S. researchers have shown that blocking S100 calcium binding protein A9 could prevent thrombosis without increasing the risk of bleeding. The findings may hand a new indication to at least two companies-InflammatoRx …

    Published on 5/29/2014
  • The DR is out

    Five years after a Genentech team proposed that DR6 was a member of a seemingly targetable pathway in Alzheimer's disease, the company and Rockefeller University have concluded that the proapoptotic pathway probably …

    Published on 5/15/2014
  • TLR4 on the surface of scleroderma

    BioLineRx's deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma. It remains unclear whether the university's TLR4 …

    Published on 5/8/2014
  • Figure 1: Bolstering cancer immunotherapy with IL-15

    Targets & Mechanisms: Leveling cancer with IL-15 Figure 1. Bolstering cancer immunotherapy with IL-15. (I) IL-15 is an immunostimulatory cytokine that typically is found pre-bound to the IL-15 receptor a-chain (IL-…

    Published on 4/24/2014
  • Leveling cancer with IL-15

    Findings that link high IL-15 levels in tumors with increased local T cell proliferation and favorable patient outcomes position the cytokine as a robust prognostic and complement ongoing efforts to develop IL-15 as a …

    Published on 4/24/2014
  • Mired in miR-25

    New evidence that miR-25 inhibition can help treat heart failure contradicts earlier results. Although the current study shows that blocking miR-25 restores SERCA2A -- and thus improves cardiac contractility -- …

    Published on 4/24/2014
  • Reversing (heart) failure in Friedreich's ataxia

    Heart failure accounts for over half the deaths in patients with Friedreich's ataxia, but there are no therapies for the neurodegenerative disease. Now, a team of French researchers has shown that i.v. frataxin gene …

    Published on 4/24/2014
  • Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases…

    Published on 4/17/2014
  • Catastrophic vacuolization

    Karolinska Institute scientists have attacked glioblastoma multiforme by inducing an unconventional cell death pathway involving catastrophic vacuolization. The team identified a small molecule that prolonged survival …

    Published on 4/10/2014
  • Positioning properdin

    Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. The researchers are…

    Published on 4/10/2014
  • Narrowing down graft stenosis

    One serious complication after coronary artery bypass graft surgery is hyperplastic growth of the transplant. Now, a U.S. team has reported that this hyperplasia is rooted in the endothelial cells lining the …

    Published on 4/3/2014
  • Insights into ependymoma

    Two independent studies have revealed targets for previously intractable ependymoma tumors: a fusion protein and epigenetic modifiers, respectively. The therapeutic potential of the targets remains to be established.

    Published on 3/27/2014
  • Zinc-ing about diabetes

    ZNT8 burst onto the scene in 2007 as a promising diabetes target, and follow-up studies suggested that stimulating the zinc transporter protein could have therapeutic benefit. A new study suggests that the preferred …

    Published on 3/13/2014
  • Table 1: Cardiovascular expressions

    Targets & Mechanisms: Heart cells: no longer undivided Table 1. Cardiovascular expressions. At least 10 companies have gene therapies in preclinical through Phase III development to treat a range of cardiovascular …

    Published on 3/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993